Literature DB >> 18226734

Cushing's Syndrome.

Rosario Pivonello1, Maria Cristina De Martino, Monica De Leo, Gaetano Lombardi, Annamaria Colao.   

Abstract

Cushing's syndrome is a rare endocrine disease characterized by cortisol hypersecretion, induced mainly by a pituitary tumor (Cushing's disease) or, rarely, by an adrenal or an ectopic neuroendocine tumor. Cushing's syndrome is associated with severe morbidities and an increased mortality. The major systemic complications and the main cause of death are represented by cardiovascular disease. The prognosis of the disease is mainly affected by the difficulties in the diagnosis and treatment of the disease, which remain a considerable challenge.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18226734     DOI: 10.1016/j.ecl.2007.10.010

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  58 in total

1.  Comparison of the efficacy of liraglutide with pioglitazone on dexamethasone induced hepatic steatosis, dyslipidemia and hyperglycaemia in albino rats.

Authors:  K Vinodraj; I M Nagendra Nayak; J Vikram Rao; Paul Mathai; N Chandralekha; B Nitasha; D Rajesh; T K Chethan
Journal:  Indian J Pharmacol       Date:  2015 Mar-Apr       Impact factor: 1.200

Review 2.  Endocrine Tumors Causing Arterial Hypertension: Pathophysiological Mechanisms and Clinical Implications.

Authors:  Agata Buonacera; Benedetta Stancanelli; Lorenzo Malatino
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-04-12

Review 3.  The management of the patient with acromegaly and headache: a still open clinical challenge.

Authors:  A Giustina; M Gola; A Colao; L De Marinis; M Losa; N Sicolo; E Ghigo
Journal:  J Endocrinol Invest       Date:  2008-10       Impact factor: 4.256

Review 4.  Molecular basis of pharmacological therapy in Cushing's disease.

Authors:  Diego Ferone; Claudia Pivonello; Giovanni Vitale; Maria Chiara Zatelli; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

5.  Outcomes of stereotactic radiosurgery and hypofractionated stereotactic radiotherapy for refractory Cushing's disease.

Authors:  Alexander D Sherry; Mohamed H Khattab; Mark C Xu; Patrick Kelly; Joshua L Anderson; Guozhen Luo; Andrea L Utz; Lola B Chambless; Anthony J Cmelak; Albert Attia
Journal:  Pituitary       Date:  2019-12       Impact factor: 4.107

Review 6.  Cushing, acromegaly, GH deficiency and tendons.

Authors:  Mariano Galdiero; Renata S Auriemma; Rosario Pivonello; Annamaria Colao
Journal:  Muscles Ligaments Tendons J       Date:  2014-11-17

7.  AT-101 acts as anti-proliferative and hormone suppressive agent in mouse pituitary corticotroph tumor cells.

Authors:  B S Yurekli; B Karaca; A Kisim; E Bozkurt; H Atmaca; S Cetinkalp; G Ozgen; C Yilmaz; S Uzunoglu; R Uslu; F Saygili
Journal:  J Endocrinol Invest       Date:  2017-07-20       Impact factor: 4.256

Review 8.  Medical therapy for Cushing's disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers.

Authors:  Maria Fleseriu; Stephan Petersenn
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

Review 9.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

10.  Treatment of Cushing disease: overview and recent findings.

Authors:  Tatiana Mancini; Teresa Porcelli; Andrea Giustina
Journal:  Ther Clin Risk Manag       Date:  2010-10-21       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.